BC Innovations | Jun 14, 2017
Distillery Therapeutics

Neurology

INDICATION: Depression Analysis of a patient adverse event database and mouse studies suggest promoting the expression of HspH1 could help treat depression. In the FDA Adverse Event Reporting System (FAERS) database, the incidence of depression...
BC Week In Review | Apr 18, 2016
Clinical News

Zepatier grazoprevir/elbasvir: Phase III data

Top-line data from the open-label, international Phase III C-EDGE Head-to-Head trial in 255 treatment-naive and treatment-experienced patients with chronic HCV genotypes 1 or 4 infection showed that once-daily oral Zepatier 50 mg elbasvir/100 mg grazoprevir...
BC Innovations | Mar 26, 2015
Translation in Brief

PK Gender Gap

A study that started out as a test of the lymphatic uptake of anticancer proteins evolved into a closer look at the effect of sex differences on cancer drug pharmacokinetics in animal models. Last year,...
BC Week In Review | May 12, 2014
Company News

Enzon infectious news

Enzon's board adopted a stockholder rights plan to reduce the likelihood of an "unintended" ownership change. Under the plan, shareholders on record on May 14 will be issued one right for each common share held....
BC Week In Review | Apr 14, 2014
Clinical News

MK-5172: Phase II data

The double-blind, dose-ranging, placebo-controlled Phase II PN038 trial in 87 treatment-naïve, non-cirrhotic patients with HCV genotype 1 infection showed that once-daily MK-5172 plus peginterferon alfa-2b and ribavirin for 12 weeks led to an SVR 12...
BC Week In Review | Mar 24, 2014
Clinical News

BIT225: Additional Phase II data

Additional data from treatment-naïve patients co-infected with HIV and chronic HCV genotype 1 or 3 infection in an open-label, Thai Phase II trial showed that all patients with HCV genotype 3 infection who received twice-daily...
BioCentury | Dec 16, 2013
Strategy

Out in the cold

New excluded drugs lists devised by pharmacy benefits managers are raising the hurdle for reimbursement of drugs the PBMs' pharmacy and therapeutics committees consider to be clinically equivalent to cheaper drugs. Drugs that are not...
BC Week In Review | Dec 9, 2013
Clinical News

BIT225: Interim Phase II data

Interim data from 12 treatment-naïve patients co-infected with HIV and chronic HCV genotype 1 or 3 infection in an open-label, Thai Phase II trial showed that all 6 patients with HCV genotype 3 infection who...
BC Week In Review | May 6, 2013
Clinical News

Simeprevir: Additional Phase III data

Medivir reported subgroup data from the double-blind, placebo-controlled, international Phase III QUEST-2 trial in 391 treatment-naive patients with HCV genotype 1 infection evaluating once-daily 150 mg oral simeprevir for 12 weeks plus Pegasys peginterferon alfa-2a...
BC Week In Review | Apr 29, 2013
Financial News

Enzon financial update

Enzon said it will distribute the company's excess cash from ongoing royalty revenues to shareholders through periodic dividends, including a special dividend of $1.60 per share to be paid on June 4 to shareholders on...
Items per page:
1 - 10 of 346